Beta1 Integrins and IGF-I Receptor in Prostate Cancer

描述（申请人提供）：整合素具有控制癌细胞增殖、存活和粘附的能力，在肿瘤进展中起重要作用。PI最近的发现揭示了β 1整合素亚家族成员和IGF-IR（胰岛素样生长因子受体）之间的一种新的分子界面，IGF-IR是一种激酶受体，已知在前列腺癌中显著上调。PI描述了一种控制前列腺癌细胞功能的新机制，该机制通过β 1整合素对IGF-IR信号的选择性调节来响应igf -刺激。通过信号复合物在其选择性剪接的细胞质结构域的差异募集，PI发现beta1A与IGF-IR的关联促进了IGF-IR刺激的细胞增殖，并阻止了igf介导的细胞与基底膜蛋白的粘附，从而可能允许肿瘤肿块扩大和侵袭。相反，beta1C细胞质整合素变体拮抗这些作用，抑制IGF-IR刺激的细胞增殖并促进与基底膜蛋白的牢固粘附。在IGF作用下，β 1整合素细胞结构域对前列腺癌细胞功能的差异调节机制是通过IGF- ir下游效应物在质膜上的差异募集来实现的。与这些发现一致的是，在前列腺癌小鼠模型中，β 1和IGF-IR在肿瘤转化的早期阶段同时上调。基于上述发现，在本应用中需要验证的假设是，β 1整合素在前列腺癌进展中调节IGF-IR信号传导和功能。在Aim 1中，我们特别计划在体外剖析β 1a - igf - ir复合物和β 1c在调节前列腺癌细胞功能中的作用。在Aim 2中，PI计划研究beta1A-IGF-IR复合物的定位，特定底物对复合物活性的调节以及beta1A-IGF-IR复合物和beta1C下游的信号通路。在Aim 3中，PI将分析β 1整合素和IGF-IR以及β 1 -IGF-IR复合物在前列腺癌进展中的体内作用。本研究旨在阐明前列腺癌中整合素和生长因子受体之间新的分子相互作用，并为前列腺癌治疗提供新的靶点验证。

DESCRIPTION (provided by applicant): Integrins' ability to control cancer cell proliferation, survival and adhesion plays an important role in tumor progression. Recent findings by the PI have unraveled a novel molecular interface between members of the beta1 integrin subfamily and IGF-IR (Insulin-like Growth Factor Receptor), a kinase receptor known to be significantly upregulated in prostate cancer. The PI describes a novel mechanism that controls prostate cancer cell functions and occurs via a selective modulation of IGF-IR signaling by beta1 integrins in response to IGF-stimulation. Through differential recruitment of signaling complexes to their alternatively spliced cytoplasmic domains, the PI found that the association of beta1A with IGF-IR promotes IGF-IR - stimulated cell proliferation and prevents IGF-mediated cell adhesion to basement membrane proteins, thus presumably allowing the tumor mass to expand and invade. In contrast, the beta1C cytoplasmic integrin variant antagonizes these effects, suppresses IGF-IR - stimulated cell proliferation and promotes firm adhesion to basement membrane proteins. The mechanism by which the beta1 integrin cytodomain differentially modulates prostate cancer cell functions in response to IGF occurs via differential recruitment to the plasma membrane of IGF-IR downstream effectors. Consistent with these findings is also the observation that both beta1 and IGF-IR are concurrently upregulated in the early stages of neoplastic transformation in a mouse model of prostate cancer. The hypothesis to be tested in the present application, based on the findings described above, is that beta1 integrins modulate IGF-IR signaling and functions in prostate cancer progression. It is specifically planned, in Aim 1, to dissect in vitro the role of the beta1A-IGF-IR complex and of beta1C in modulating prostate cancer cell functions. In Aim 2, the PI plans to study the localization of the beta1A-IGF-IR complex, the modulation of the activity of the complex by specific substrates as well as the signaling pathways downstream of the beta1A-IGF-IR complex and of beta1C. In Aim 3, the PI will analyze in vivo the role of beta1 integrins and IGF-IR and of the beta1A-IGF-IR complex in prostate cancer progression. This study is designed to elucidate novel molecular interactions between integrins and growth factor receptors in prostate cancer and will allow new target validation in prostate cancer therapy.